Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Galapagos
Biotech
Galapagos took €228M hit from cell therapy wind-down
Despite the strategic shift, the Belgian biopharma is confident it can stabilize its finances by the end of the year.
James Waldron
Feb 24, 2026 6:30am
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
Fierce Biotech's Rotten Tomatoes of 2025
Dec 16, 2025 4:30am
'Gilead wants us to rebuild': Why Galapagos can't go extinct
Nov 19, 2025 7:50am
Galapagos to wind down cell therapy unit, threatening 365 jobs
Oct 21, 2025 9:30am
Ikena and Inmagene choose combined CEO—Chutes & Ladders
Jul 25, 2025 8:30am
